Tamoxifen is widely used in the treatment of breast cancer and associated with an increased risk of thromboembolism (TE). An elevated homocysteine is one of the risk factors for TE. The aim of the study was to assess the effect of tamoxifen on serum homocysteine levels in breast cancer patients. We performed a case-control study in 20 female subjects to evaluate the relationship between homocysteine levels, and 5,10-methylenetetrahyrofolate reductase (MTHFR) C677T and dihydrofolate reductase (DHFR) 19-bp intron-1 deletion polymorphisms in breast cancer patients and in control subjects. It was observed that homocysteine levels were decreased during tamoxifen therapy, but this finding was not statistically significant. There was also no statistically significant difference in homocysteine levels between the two groups (p> 0.05). MTHFR C677T and DHFR 19-bp deletion polymorphisms were not associated with serum homocysteine value in either group.
Introduction
Thromboembolism (TE) is well-recognized complication of cancer and its treatment [1] . The pathogenesis of the prothrombotic state in cancer is complex and reflects the interplay between environmental, clinical, and genetic factors. Tamoxifen is widely used as adjuvant therapy in the treatment of pre-and post-menopausal patients with breast cancer. There are several reports on the increased incidence of TE associated with tamoxifen [2, 3] . Some authors have also indicated that the risk of TE is increased two-to threefold during tamoxifen use for breast cancer chemoprevention [4, 5] .
Hyperhomocysteinemia is an important risk factor for thrombosis. Dihydrofolate reductase (DHFR) and metylenetetrahyrofolate reductase (MTHFR) are important folate metabolizing enzymes that are essential for DNA synthesis and homocysteine remethylation. In addition, these enzymes are suspected to be associated with breast cancer development, via their effects on DNA methylation and nucleotide synthesis. Recently, we investigated the association of breast cancer risk with MTHFR C677T and DHFR 19-bp intron-1 deletion polymorphisms [6] . In the present report, we have evaluated the effects of MTHFR C677T and DHFR 19-bp intron-1 deletion polymorphisms on serum homocysteine levels in breast cancer patients treated with tamoxifen and in healthy women subjects.
Material and Methods
The study consisted of 10 breast cancer patients taking tamoxifen (group 1) and 10 healthy women (in matched control, group 2). The breast cancer patients were recruited at the Department of General Surgery, Konya Numune State Hospital and were treated by one surgeon (A.E.). Age matched controls were selected from registered data at Department of Pediatric Molecular Genetic, Ankara University Medical School. Written informed consent was obtained from all participating subjects.
Fasting blood samples from breast cancer cases were obtained at baseline before tamoxifen treatment and then at 3, 6, 12, and 24 weeks. All blood samples were promptly centrifuged and the serum was stored at -70 0 C. Total serum homocysteine levels were determined by chemiluminescent method using ADVIA Centaur ® System (Bayer HealthCare, NY, USA). Genomic DNA isolation was performed from peripheral venous blood by standard phenolchlorophorm extraction, and polymerase chain reaction of 19-bp deletion polymorphism in intron-1 of DHFR and MTHFR C677T polymorphism were performed according to previously described method [6] . In briefly, MTHFR C677T polymorphism was determined by using commercially available LightCycler kit (Roche Diagnostic, Roche Molecular Biochemicals, Mannheim, Germany). The following primers were used for DHFR 19-bp deletion intron-1 polymorphism: F 5'-CCACGGTCGGGGTACCTGGG-3', F 5'-ACGGTCGGGGTGGCCGACTC-3' and R 5'-AAAAGGGGAATCCAGTCGG-3'. Amplification was made as follows: initial denaturation of one min at 94 0 C; followed by 35 cycles of 94 0 C / 55 s, 64 0 C / 55 s, 72 0 C / 55 s, and final extension of 12 min at 72 0 C (Biometra, Germany). The resulting PCR products were 96-bp and 113-bp. For further identification, amplified DNA products were run on a 4% agarose gel. The results of the homocysteine level measurements were expressed as the mean + standard deviation (SD). We performed the Mann-Whitney U test to evaluate the influences of MTHFR C677T and DHFR 19-bp deletion polymorphisms on serum homocysteine levels between the two groups. In addition, we performed the Mann-Whitney U test to compare serum homocysteine levels between the control group and the baseline value of the breast cancer group (at baseline value before tamoxifen therapy). We applied the Freidman test to assess changes between baseline levels of serum homocysteine and the blood levels at the following time points for each breast cancer patient: 3-wks, 6-wks, 12-wks, and 24 wks. For all tests, a p-value < 0.05 was accepted as significant. The statistical analysis was performed by SPSS software (SPSS Inc, Chicago, IL).
Results
The distribution of MTHFR C677T and DHFR 19-bp deletion polymorphisms in breast cancer patients and control subjects are listed in Table 1 . The mean value of homocysteine level was lower in control subjects compared with baseline values of breast cancer patients (11.65 + 2.8 vs. 13.6 + 3.2 µmol /U), but the difference was not statistically significant (p=0.253) (Figure 1) . The and breast cancer patients (at baseline value before tamoxifen) (group 2). WT: wild type; del: deletion distribution of mean homocysteine values on the basis MTHFR C677T and DHFR 19-bp deletion polymorphisms in both two groups were found to be statistically insignificant (p> 0.05) ( Table 2 ). As shown Figure 2 , the changes of homocysteine values during tamoxifen therapy were not significantly different from its baseline value in group 2 patients (p= 0.362, Friedman test).
Control

Discussion
Several studies have investigated measurements of hemostasis in patients taking tamoxifen, however the mechanisms for its procoagulants effect have not been clearly identified. Moreover, the results have been conflicting, and important alterations have not been identified [7] [8] [9] [10] . Previously, we indicated that the risk of TE during tamoxifen therapy was increased in breast cancer patients with factor V Leiden mutation [11] . In the present study, we evaluated the effect of tamoxifen on serum homocysteine levels and the relationship between its serum level and MTHFR C677T and DHFR 19-bp deletion polymorphisms. It is known that hyperhomocysteinemia is important for thrombosis [12] . Mutations or polymorphisms of critical enzymes involved in homocysteine metabolism may influence the risk of thrombosis. MTHFR is a key enzyme in foliate-mediated 1-carbon metabolism, regulating the DNA methylation and synthesis. The common MTHFR 677 C-T causing an Ala to Val protein change, results in the thermolabile form of MTHFR that is associated with reduced enzyme activity thereby increasing plasma homocysteine level.
DHFR is also important folate metabolizing enzyme that is essential for DNA synthesis and homocysteine remethylation. Recently, Gellekink et al. reported that 19-bp del/del genotype of DHFR was associated with a lower plasma homocysteine level and suggested that 19-bp deletion might increase DHFR expression thereby facilitating homocysteine re-methylation [13] .
In the present study, we have therefore investigated the effects of MTHFR C677T and DHFR 19-bp intron-1 deletion polymorphisms on serum homocysteine levels in breast cancer patients treated with tamoxifen. It was found that these polymorphisms were not associated with serum homocysteine levels in breast cancer patients. Although our case number was small, based on our results it can be said that MTHFR G677T and DHFR 19-bp del polymorphisms are not correlated with serum homocysteine levels. However, further larger series are necessary to better understand the effects of these polymorphisms on homocysteine level before a final conclusion.
In agreement with previous reports [9, 10] , we observed that tamoxifen therapy was associated with the lowering of serum homocysteine levels, but these changes were not significant. Although the number of our study subjects was small, from our results, we might surmise that tamoxifen treatment does not significantly influence serum homocysteine levels. Furthermore, our previous results failed to find a significant difference in homocysteine levels between breast cancer patients and control subjects. However, further studies with larger series are needed.
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